<DOC>
	<DOC>NCT00156273</DOC>
	<brief_summary>We are trying to develop better ways to detect when cancer therapies are working.</brief_summary>
	<brief_title>Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1.Females at least 18 years of age 2 Diagnosis of metastatic breast cancer 3.ECOG Score of 02 4.Treating oncologist has decided to initiate any new systemic therapy with emphasis on recruiting patients commencing a taxanebased regimen. Taxinebased therapy may be docetaxel or paclitaxel, and it can be given on any schedule,including weekly or every 3 weeks. Other treatment can include nontaxane chemotherapy or trastuzumabwith or without other therapy. 5.Patient is willing to return for one or more additional ~18 mL blood draw (s) at 2448, and /or 72 hours and ~34 weeks after the initiation of therapy.At a minimum, patients must donate blood at baseline, one intermediate interval (24, 48, 72 hr) and at ~34 weeks 6.Signed Informed Consent Form Patient is unable and unwilling to provide a blood specimen at a minimum of one of the intermediate blood draw time points at 24, 48, or 72 hours</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>